{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T14:14:40Z","timestamp":1762265680406,"version":"build-2065373602"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007957","name":"Chongqing Municipal Education Commission","doi-asserted-by":"publisher","award":["KJQN202200465"],"award-info":[{"award-number":["KJQN202200465"]}],"id":[{"id":"10.13039\/501100007957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005230","name":"Natural Science Foundation of Chongqing Municipality","doi-asserted-by":"publisher","award":["CSTB2024NSCQ-MSX0261"],"award-info":[{"award-number":["CSTB2024NSCQ-MSX0261"]}],"id":[{"id":"10.13039\/501100005230","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002338","name":"Ministry of Education of the People's Republic of China","doi-asserted-by":"publisher","award":["CNTTI20240004"],"award-info":[{"award-number":["CNTTI20240004"]}],"id":[{"id":"10.13039\/501100002338","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22477012"],"award-info":[{"award-number":["22477012"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ejmech.2025.118050","type":"journal-article","created":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T14:49:30Z","timestamp":1754750970000},"page":"118050","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Identification and structure-activity relationship optimization of dibromoacetophenones as novel mIDH1 inhibitors"],"prefix":"10.1016","volume":"299","author":[{"given":"Cong","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiying","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haibo","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaming","family":"Ou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2259-7704","authenticated-orcid":false,"given":"Shao-Lin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118050_bib1","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/ncb3124","article-title":"Metabolic pathways promoting cancer cell survival and growth","volume":"17","author":"Boroughs","year":"2015","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.118050_bib2","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1158\/1078-0432.CCR-17-3070","article-title":"Oxidative phosphorylation as an emerging target in cancer therapy","volume":"24","author":"Ashton","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118050_bib3","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.drudis.2015.03.012","article-title":"Development of pyruvate dehydrogenase kinase inhibitors in medicinal chemistry with particular emphasis as anticancer agents","volume":"20","author":"Zhang","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2025.118050_bib4","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg effect: the metabolic requirements of cell proliferation","volume":"324","author":"Vander Heiden","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.118050_bib5","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.drudis.2018.05.014","article-title":"Targeting cancer metabolism to develop human lactate dehydrogenase (hLDH)5 inhibitors","volume":"23","author":"Zhang","year":"2018","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2025.118050_bib6","doi-asserted-by":"crossref","first-page":"8981","DOI":"10.1021\/acs.jmedchem.8b00159","article-title":"Inhibitors of mutant isocitrate dehydrogenases 1 and 2 (mIDH1\/2): an update and perspective","volume":"61","author":"Ma","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118050_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116610","article-title":"Discovery of novel natural-product-derived mutant isocitrate dehydrogenases 1 inhibitors: structure-based virtual screening, biological evaluation and structure-activity relationship study","volume":"275","author":"Xu","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118050_bib8","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.apsb.2022.12.019","article-title":"The regulatory mechanisms and inhibitors of isocitrate dehydrogenase 1 in cancer","volume":"13","author":"Liu","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2025.118050_bib9","doi-asserted-by":"crossref","first-page":"12894","DOI":"10.1021\/acs.jmedchem.3c00835","article-title":"Structure-based drug design of novel triaminotriazine derivatives as orally bioavailable IDH2R140Q inhibitors with high selectivity and reduced hERG inhibitory activity for the treatment of acute myeloid leukemia","volume":"66","author":"Wei","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118050_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117041","article-title":"Comprehensive exploration of isocitrate dehydrogenase (IDH) mutations: tumorigenesis, drug discovery, and covalent inhibitor advances","volume":"282","author":"Gai","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118050_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115464","article-title":"Challenges for the development of mutant isocitrate dehydrogenases 1 inhibitors to treat glioma","volume":"257","author":"Wang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118050_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112491","article-title":"Structure-based design, synthesis and bioactivity evaluation of macrocyclic inhibitors of mutant isocitrate dehydrogenase 2 (IDH2) displaying activity in acute myeloid leukemia cells","volume":"203","author":"Che","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118050_bib13","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJMoa0808710","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"360","author":"Yan","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118050_bib14","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118050_bib15","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/path.2913","article-title":"IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumors","volume":"224","author":"Amary","year":"2011","journal-title":"J. Pathol."},{"key":"10.1016\/j.ejmech.2025.118050_bib16","article-title":"IDH inhibitors in advanced cholangiocarcinoma: another arrow in the quiver?","volume":"27","author":"Rizzo","year":"2021","journal-title":"Cancer Treat Res. Commun."},{"key":"10.1016\/j.ejmech.2025.118050_bib17","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nature08617","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"462","author":"Dang","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.118050_bib18","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/neuonc\/nov136","article-title":"Isocitrate dehydrogenase mutations in gliomas","volume":"18","author":"Waitkus","year":"2016","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ejmech.2025.118050_bib19","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.1021\/acs.jmedchem.1c00019","article-title":"Discovery and optimization of 2H-1\u03bb2-Pyridin-2-one inhibitors of mutant isocitrate dehydrogenase 1 for the treatment of cancer","volume":"64","author":"Rohde","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118050_bib20","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1101\/gad.198200.112","article-title":"D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function","volume":"26","author":"Sasaki","year":"2012","journal-title":"Genes Dev."},{"key":"10.1016\/j.ejmech.2025.118050_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111694","article-title":"Discovery of new small molecule inhibitors targeting isocitrate dehydrogenase 1 (IDH1) with blood-brain barrier penetration","volume":"183","author":"Cao","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118050_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115411","article-title":"Structure-based discovery of IHMT-IDH1-053 as a potent irreversible IDH1 mutant selective inhibitor","volume":"256","author":"Liang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118050_bib23","doi-asserted-by":"crossref","first-page":"8307","DOI":"10.1021\/jm500660f","article-title":"Inhibition of cancer-associated mutant isocitrate dehydrogenases: synthesis, structure-activity relationship, and selective antitumor activity","volume":"57","author":"Liu","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118050_bib24","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1074\/jbc.M114.608497","article-title":"Selective inhibition of mutant isocitrate dehydrogenase 1 (IDH1) via disruption of a metal binding network by an allosteric small molecule","volume":"290","author":"Deng","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.118050_bib25","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/annonc\/mdz244.020","article-title":"efficacy, PK and PD biomarker results of the first-in-human study of mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor BAY 1436032 in patients (pts) with mIDH1 advanced solid tumours","volume":"30","author":"Wick","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2025.118050_bib26","doi-asserted-by":"crossref","first-page":"6899","DOI":"10.1021\/acs.jmedchem.5b00684","article-title":"Inhibition of cancer-associated mutant isocitrate dehydrogenases by 2-thiohydantoin compounds","volume":"58","author":"Wu","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118050_bib27","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1021\/acsmedchemlett.9b00509","article-title":"Vorasidenib (AG-881): a first-in-class, brain-penetrant dual inhibitor of mutant IDH1 and 2 for treatment of glioma","volume":"11","author":"Konteatis","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118050_bib28","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1007\/s40265-024-02097-2","article-title":"Vorasidenib: first approval","volume":"84","author":"Lamb","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.118050_bib29","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/nchembio.1930","article-title":"New IDH1 mutant inhibitors for treatment of acute myeloid leukemia","volume":"11","author":"Okoye-Okafor","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.118050_bib30","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1021\/acsmedchemlett.7b00421","article-title":"Discovery of AG-120 (ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers","volume":"9","author":"Popovici-Muller","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118050_bib31","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1021\/acs.jmedchem.9b01423","article-title":"Structure-based design and identification of FT-2102 (Olutasidenib), a potent mutant-selective IDH1 inhibitor","volume":"63","author":"Caravella","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118050_bib32","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41698-022-00304-5","article-title":"Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma","volume":"6","author":"Cleary","year":"2022","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.ejmech.2025.118050_bib33","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1182\/blood.2020007233","article-title":"Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study","volume":"137","author":"Stein","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.118050_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113225","article-title":"Synthesis, biological evaluation and structure-activity relationship of novel dichloroacetophenones targeting pyruvate dehydrogenase kinases with potent anticancer activity","volume":"214","author":"Xu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118050_bib35","doi-asserted-by":"crossref","first-page":"8040","DOI":"10.1021\/acs.jmedchem.2c00615","article-title":"Optimization of the natural product calothrixin A to discover novel dual topoisomerase I and II inhibitors with improved anticancer activity","volume":"65","author":"Yang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118050_bib36","doi-asserted-by":"crossref","first-page":"9955","DOI":"10.1021\/acs.jmedchem.2c00640","article-title":"A mitochondria-targeted phenylbutyric acid prodrug confers drastically improved anticancer activities","volume":"65","author":"Huang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118050_bib37","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ejmech.2018.06.012","article-title":"Rational design of mitochondria-targeted pyruvate dehydrogenase kinase 1 inhibitors with improved selectivity and antiproliferative activity","volume":"155","author":"Xu","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118050_bib38","doi-asserted-by":"crossref","first-page":"11852","DOI":"10.1021\/acs.jmedchem.5c00701","article-title":"Unexpected discovery of a novel triphenylphosphonium alkylalcohol that triggers cancer cell death via mitophagy and ferroptosis","volume":"68","author":"Huang","year":"2025","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425008153?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425008153?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T14:10:06Z","timestamp":1762265406000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425008153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":38,"alternative-id":["S0223523425008153"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118050","relation":{},"ISSN":["0223-5234"],"issn-type":[{"type":"print","value":"0223-5234"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification and structure-activity relationship optimization of dibromoacetophenones as novel mIDH1 inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118050"}}